Cargando…

Long-Lasting, Patient-Controlled, Procedure-Free Contraception: A Review of Annovera with a Pharmacist Perspective

Annovera (segesterone acetate and ethinyl estradiol vaginal system) is a US Food and Drug Administration FDA-approved long-lasting, reversible contraceptive that is fully administered by the user and does not require a procedure for insertion or removal. The vaginal system is in the shape of a ring...

Descripción completa

Detalles Bibliográficos
Autores principales:	Virro, Jennifer J., Besinque, Kathleen, Carney, Christiane E., Gross, Danielle, Bernick, Brian, Mirkin, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558341/ https://www.ncbi.nlm.nih.gov/pubmed/32872116 http://dx.doi.org/10.3390/pharmacy8030156

Ejemplares similares

New Contraception Update — Annovera, Phexxi, Slynd, and Twirla
por: Baker, Courtney C., et al.
Publicado: (2022)

SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
por: Liu, James H, et al.
Publicado: (2020)

SAT-219 A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins
por: Archer, David, et al.
Publicado: (2019)

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

Pharmacists and Contraception in the Inpatient Setting
por: Ciriello, Domenique, et al.
Publicado: (2020)

SAT-239 Bioidentical Estradiol and Progesterone Improved Hot Flushes, Night Sweats and Sweating
por: Liu, James, et al.
Publicado: (2019)

Systemic estradiol levels with low-dose vaginal estrogens
por: Santen, Richard J., et al.
Publicado: (2019)

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review
por: Constantine, Ginger D., et al.
Publicado: (2019)

Opinions of West Texas pharmacists about emergency contraception
por: Sutkin, Gary, et al.
Publicado: (2006)

Accessibility of Pharmacist-Prescribed Contraceptives in Utah
por: Magnusson, Brianna M., et al.
Publicado: (2021)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

The MATE survey: men's perceptions and attitudes towards menopause and their role in partners’ menopausal transition
por: Parish, Sharon J., et al.
Publicado: (2019)

Pharmacist-Prescribed Hormonal Contraception: Does Didactic Hormonal Contraception Education Affect Student Pharmacist Perceptions of This Professional Activity?
por: Rikard, Rachel, et al.
Publicado: (2021)

A Qualitative Study of Prescription Contraception Use: The Perspectives of Users, General Practitioners and Pharmacists
por: Sweeney, Leigh-Ann, et al.
Publicado: (2015)

Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy
por: Pickar, James H., et al.
Publicado: (2015)

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms
por: Santoro, Nanette, et al.
Publicado: (2019)

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial
por: Black, Denise R., et al.
Publicado: (2020)

Opposition to Pharmacist Contraception Services: Evidence for Rebuttal
por: Mitchell, Madeline, et al.
Publicado: (2020)

Role of Pharmacists in Hormonal Contraceptive Access: A Survey of North Carolina Pharmacists
por: Seamon, Gwen J, et al.
Publicado: (2020)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

Emergency Contraception and the Knowledge of Community Pharmacists in Isfahan, Iran
por: Mostafavi, Sayed Abolfazl, et al.
Publicado: (2011)

Association of Pharmacist Prescription With Dispensed Duration of Hormonal Contraception
por: Rodriguez, Maria I., et al.
Publicado: (2020)

Beyond Contraception: Pharmacist Roles to Support Maternal Health
por: DiPietro Mager, Natalie, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol
por: Pickar, James H., et al.
Publicado: (2016)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
por: Liu, James H., et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

MON-006 Progesterone Receptor Expression in Endometrial Biopsies After 12 Weeks of Exposure to A 4-µg E2 Softgel Vaginal Insert or Placebo
por: Simon, James A, et al.
Publicado: (2020)

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
por: Mirkin, Sebastian, et al.
Publicado: (2020)

Alaska pharmacists: First responders to the pandemic in the last frontier
por: Paul, Amy K., et al.
Publicado: (2021)

Enhancing access to contraception through pharmacist prescribing across Canada
por: Soon, Judith A., et al.
Publicado: (2021)

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries
por: Constantine, Ginger D, et al.
Publicado: (2016)

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women
por: Constantine, Ginger D., et al.
Publicado: (2017)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
por: Constantine, Ginger D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7dq3298nl0smv5008k4n6ftep0